Thursday, October 09, 2014

Price Transparency Benefits Hospital Patients

›
Internet access has ushered in an era of price transparency, where shoppers wielding smartphones check prices before deciding where to bu...
Monday, September 29, 2014

Watching Television for Allergy Relief

›
Looking to master the quiet sneeze or get relief from those itchy, watery eyes? If so, consider watching television, at least long enou...
Friday, September 26, 2014

Can Conatus Pharmaceuticals Duplicate Intercept's Success?

›
Conatus Pharmaceuticals (CNAT-$6.03) is developing a first-in-class, orally active pan-caspase protease inhibitor, called emricasan, which...
Monday, September 08, 2014

Keryx Biopharmaceutical's Kidney Drug Approved - What Now?

›
Keryx Biopharmaceuticals, Inc.   (KERX-$17.01) announced that the FDA approved Ferric Citrate (formerly known as Zerenex) for the contr...
Tuesday, August 19, 2014

PropThink Readers Profit from Amicus Therapeutics Buy Recommendation

›
Premium readers over at PropThink.com are already up 15% since our buy recommendation was issued on  Amicus Therapeutics [FOLD]  on Augu...
Tuesday, August 12, 2014

OncoGeneX Checkup

›
I gnore OncoGeneX’s (OGXI-$3.15) reported second-quarter 2014 loss of 47 cents per share. Investors, instead, should focus on existing...
Thursday, July 31, 2014

Making Sense on OncoGeneX

›
OncoGeneX’ s (OGXI - $2.98)  stock collapsed in the last four months, losing almost 80% in market value after reporting that its lead asse...
1 comment:
Wednesday, June 11, 2014

Conatus Pharma Breaks From Intercept's Shadow?

›
Bloggers and traders alike are scratching their heads, looking for answers as to why Conatus Pharmaceuticals (CNAT) is up more than 48%...
Friday, May 02, 2014

Agios Impresses With Leukemia Drug: Investor Beware

›
Agios Pharmaceuticals (AGIO-$43.35)   moved substantially higher in price last month after   reporting   Phase 1 data demonstrating that ...

Biotech Losers of 2013: AVEO, INFI, AFFY, and ARIA -- Where Are They Now?

›
Despite having lost more than 90% of its market valuation in the last 21 months, AVEO Pharma’s (AVEO-$1.24)  management believes it can d...
Thursday, April 03, 2014

AbbVie's IV Lifeline Still Humira

›
Investors in AbbVie (ABBV-$53.34) are reminded each quarterly earnings release of the continued importance of Humira to the drug maker...
Tuesday, March 18, 2014

AbbVie Hums with Humira

›
AbbVie (ABBV - $53.10) Chief executive Rick Gonzalez told analysts on the   fourth-quarter earnings call  that management expects global...
1 comment:

Pfizer's Strategic Move into Opioid Analgesics

›
Pfizer's (PFE-$31.93) management stated during the  fourth-quarter 2013 earnings call   last month that a move toward opioid analgesi...

Ignore the Zogenix Buzz

›
Though Zogenix (ZGNX-$3.55) is entering a chronic pain market with estimated annual sales worth an estimated $15.5 billion, the market i...
Thursday, February 20, 2014

Progenics Pharmaceuticals: New Front in War Against Cancer

›
Investors’ bearish sentiment that further testing of the clinical utility of Progenics Pharma’s (PGNX-$5.00) PSMA-ADC might be pointless...
Monday, February 17, 2014

The New Old Yahoo Under Marissa Mayer

›
Yahoo (YHOO-$38.23) continues to fall further behind Google (GOOG) and Microsoft (MSFT) in organic growth for inquiring eyes (and pote...
Monday, February 10, 2014

Lobbying Momentum to Drive Pharmacyclics Success?

›
In addition to hard science, lobbying momentum could be another catalyst driving sales of Pharmacyclics (PCYC-$131.38) new blood cancer ...
Saturday, January 25, 2014

Pharmacyclic's Imbruvica: New Hope for Cancer Patients

›
Imbruvica, by  Pharmacyclics (PCYC-$135.20),  received accelerated approval for MCL based on a study where 111 participants were given I...
1 comment:
Saturday, January 11, 2014

Checking for Signs of Life at Vivus

›
Led by new chief executive Seth Fischer, Vivus (VVUS-$9.18) is walking a new path with its erectile dysfunction (ED) drug Stendra (ava...
Monday, December 23, 2013

SolarCity's Bright Growth Prospects

›
Founded in 2006 with the initial objective of selling solar energy systems outright, SolarCity (SCTY-$55.60) has since embraced the conc...